Insulin-like growth factor mRNA binding protein 3 (IMP3) is differentially expressed in benign and malignant follicular patterned thyroid tumors

Endocrine Pathology

Volumn 20, Issue 3, 2009, Pages 149-157

  Slosar, Magdalena ^a   Vohra, Poonam ^a   Prasad, Manju ^a   Fischer, Andrew ^a   Quinlan, Robert ^b   Khan, Ashraf ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b UMASS MEMORIAL MEDICAL CENTER   (United States)

Author keywords

Follicular; Immunohistochemistry; IMP3; Thyroid; Tumor

Indexed keywords

MESSENGER RNA; MONOCLONAL ANTIBODY; SOMATOMEDIN BINDING PROTEIN 3; IMP 3 PROTEIN, HUMAN; IMP-3 PROTEIN, HUMAN; RNA BINDING PROTEIN; TUMOR MARKER; TUMOR PROTEIN;

ADENOMA; ADULT; AGED; ANAPLASTIC CARCINOMA; ARTICLE; CANCER INVASION; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FOLLICULAR ADENOMA; FOLLICULAR CARCINOMA; GENE EXPRESSION; GENE FUNCTION; GRAVES DISEASE; HASHIMOTO DISEASE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPERPLASTIC COLLOID NODULE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPH VESSEL; MAJOR CLINICAL STUDY; ONCOCYTOMA; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SENSITIVITY AND SPECIFICITY; THYROID DISEASE; THYROID FOLLICULAR CARCINOMA; THYROID PARAFOLLICULAR CELL; TISSUE DISTRIBUTION; TUMOR DIFFERENTIATION; TUMOR VOLUME; ADENOCARCINOMA; BIOSYNTHESIS; FEMALE; GENETICS; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; THYROID TUMOR;

ADENOCARCINOMA, FOLLICULAR; ADULT; AGED; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM PROTEINS; RNA, MESSENGER; RNA-BINDING PROTEINS; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 70449714135     PISSN: 10463976     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12022-009-9079-x     Document Type: Article

References (38)

1. Baloch ZW, Livolsi VA. Follicular-patterned lesions of the thyroid: the bane of the pathologist. Am J Clin Pathol. 2002;17 (1):143-150. doi:10.1309/8VL9-ECXY-NVMX-2RQF. (Pubitemid 34052484)
2. Khan AN, V. Pathology of Thyroid Gland. In: Lloyd RV, ed. Endocrine Pathology: Differential Diagnosis and Molecular Advances. Totowa, NJ: Humana Press Inc.; 2003:153-189.
3. Rezk S, Khan A. Role of immunohistochemistry in the diagnosis and progression of follicular epithelium-derived thyroid carcinoma. Appl Immunohistochem Mol Morphol 13(3):256-264, 2005. doi:10.1097/01.pai.0000142823. 56602.fe. (Pubitemid 41209020)
4. Saggiorato E, De Pompa R, Volante M, et al. Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. Endocr-Relat Cancer 12(2):305-317, 2005. doi:10.1677/erc.1.00944. (Pubitemid 40896449)
5. Savin S, Cvejic D, Isic T, Paunovic I, Tatic S, Havelka M. The efficacy of the thyroid peroxidase marker for distinguishing follicular thyroid carcinoma from follicular adenoma. Experimental oncology 2006;28(1):70-4, 2006.
6. Wang S, Lloyd RV, Hutzler MJ, et al. Expression of eukaryotic translation initiation factors 4E and 2alpha correlates with the progression of thyroid carcinoma. Thyroid 11(12):1101-1107, 2001. doi:10.1089/10507250152740939.
7. Wang S, Lloyd RV, Hutzler MJ, Safran MS, Patwardhan NA, Khan A. The role of cell cycle regulatory protein, cyclin D1, in the progression of thyroid cancer. Mod Pathol 13(8):882-887, 2000. doi:10.1038/modpathol.3880157. (Pubitemid 30643836)
8. Wang S, Wuu J, Savas L, Patwardhan N, Khan A. The role of cell cycle regulatory proteins, cyclin D1, cyclin E, and p27 in thyroid carcinogenesis. Human Pathol 29(11):1304-9, 1998. doi:10.1016/ S0046-8177(98)90262-90263 (Pubitemid 28525534)
9. Bartolazzi A, Gasbarri A, Papotti M, et al. Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet. 2001;357(9269):1644-1650. doi:10.1016/S0140-6736(00)04817-0. (Pubitemid 32568236)
10. Khan A, Baker SP, Patwardhan NA, Pullman JM. CD57 (Leu-7) expression is helpful in diagnosis of the follicular variant of papillary thyroid carcinoma. Virchows Arch. 1998;5:427-432. doi:10.1007/s004280050186. (Pubitemid 28266198)
11. Scognamiglio T, Hyjek E, Kao J, Chen YT. Diagnostic usefulness of HBME1, galectin-3, CK19, and CITED1 and evaluation of their expression in encapsulated lesions with questionable features of papillary thyroid carcinoma. Am J Clin Pathol 126(5):700-708, 2006. doi:10.1309/044V86JN2W3CN5YB. (Pubitemid 44707620)
12. Ito Y, Yoshida H, Tomoda C, et al. Galectin-3 expression in follicular tumours: an immunohistochemical study of its use as a marker of follicular carcinoma. Pathology 37(4):296-298, 2005. doi:10.1080/00313020500169545. (Pubitemid 41208326)
13. Mehrotra P, Okpokam A, Bouhaidar R, et al. Galectin-3 does not reliably distinguish benign from malignant thyroid neoplasms. Histopathology 45(5):493-500, 2004. doi:10.1111/j.1365- 2559.2004.01978.x. (Pubitemid 39524324)
14. Mueller-Pillasch F, Lacher U, Wallrapp C, et al. Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene 14(22):2729-2733, 1997. doi:10.1038/sj.onc.1201110. (Pubitemid 27283112)
15. Mueller-Pillasch F, Pohl B, Wilda M, et al. Expression of the highly conserved RNA binding protein KOC in embryogenesis. Mech Dev 88(1):95-99, 1999. doi:10.1016/S0925-4773(99)00160-4. (Pubitemid 29467415)
16. Yantiss RK, Woda BA, Fanger GR, et al. KOC (K homology domain containing protein overexpressed in cancer): a novel molecular marker that distinguishes between benign and malignant lesions of the pancreas. Am J Surg Pathol 29(2):188-195, 2005. doi:10.1097/01.pas.0000149688.98333.54. (Pubitemid 40170636)
17. Hanley KZ, Facik MS, Bourne PA, et al. Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions. Cancer 114(1):49-56, 2008. doi:10.1002/cncr.23254. (Pubitemid 351304612)
18. Jiang Z, Chu PG, Woda BA, et al. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol 7(7):556-564, 2006. doi:10.1016/S1470-2045(06)70732-X. (Pubitemid 43923666)
19. Jiang Z, Lohse CM, Chu PG, et al. Oncofetal protein IMP3: a novel molecular marker that predicts metastasis of papillary and chromophobe renal cell carcinomas. Cancer 112(12):2676-2682, 2008. doi:10.1002/cncr.23484. (Pubitemid 351969211)
20. Li C, Rock KL, Woda BA, Jiang Z, Fraire AE, Dresser K. IMP3 is a novel biomarker for adenocarcinoma in situ of the uterine cervix: an immunohistochemical study in comparison with p16 (INK4a) expression. Mod Pathol 20(2):242-247, 2007. doi:10.1038/ modpathol.3800735. (Pubitemid 46422179)
21. Simon R, Bourne PA, Yang Q, et al. Extrapulmonary small cell carcinomas express K homology domain containing protein overexpressed in cancer, but carcinoid tumors do not. Human Pathol 38 (8):1178-1183, 2007. doi:10.1016/j.humpath.2007.02.001. (Pubitemid 47058168)
22. Wang T, Fan L, Watanabe Y, et al. L523S, an RNA-binding protein as a potential therapeutic target for lung cancer. Br J Cancer 88(6):887-894, 2003. doi:10.1038/sj.bjc.6600806. (Pubitemid 36520876)
23. Zhang JY, Chan EK, Peng XX, Tan EM. A novel cytoplasmic protein with RNA-binding motifs is an autoantigen in human hepatocellular carcinoma. J Exp Med 189(7):1101-1110, 1999. doi:10.1084/jem.189.7.1101. (Pubitemid 29169827)
24. Zheng W, Yi X, Fadare O, et al. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma. Am J Surg Pathol 32(2):304-315, 2008. doi:10.1097/PAS.0b013e3181483ff8. (Pubitemid 351172146)
25. Mueller F, Bommer M, Lacher U, et al. KOC is a novel molecular indicator of malignancy. Br J Cancer 88(5):699-701, 2003. doi:10.1038/sj.bjc.6600790. (Pubitemid 36411447)
26. Asa SL. The role of immunohistochemical markers in the diagnosis of follicular-patterned lesions of the thyroid. Endocr Pathol 16(4):295-309, 2005. doi:10.1385/EP:16:4:295. (Pubitemid 43787106)
27. Fonseca E, Soares P, Cardoso-Oliveira M, Sobrinho-Simoes M. Diagnostic criteria in well-differentiated thyroid carcinomas. Endocr Pathol 17(2):109-117, 2006. doi:10.1385/EP:17:2:109. (Pubitemid 44965899)
28. Cheung CC, Ezzat S, Freeman JL, Rosen IB, Asa SL. Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol 14(4):338-342, 2001. doi:10.1038/modpathol.3880312. (Pubitemid 32298919)
29. Mai KT, Ford JC, Yazdi HM, Perkins DG, Commons AS. Immunohistochemical study of papillary thyroid carcinoma and possible papillary thyroid carcinoma-related benign thyroid nodules. Pathol Res Pract 196(8):533-540, 2000.
30. Raphael SJ, Apel RL, Asa SL. Brief report: detection of highmolecular- weight cytokeratins in neoplastic and non-neoplastic thyroid tumors using microwave antigen retrieval. Mod Pathol 8 (8):870-872, 1995.
31. Raphael SJ, McKeown-Eyssen G, Asa SL. High-molecular-weight cytokeratin and cytokeratin-19 in the diagnosis of thyroid tumors. Mod Pathol 7(3):295-300, 1994.
32. Sahoo S, Hoda SA, Rosai J, DeLellis RA. Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma: a note of caution. Am J Clin Pathol 116(5):696-702, 2001. doi:10.1309/6D9D-7JCM-X4T5-NNJY. (Pubitemid 34453210)
33. Goretzki PE, Simon D, Dotzenrath C, Schulte KM, Roher HD. Growth regulation of thyroid and thyroid tumors in humans. World J Surg 24(8):913-922, 2000. doi:10.1007/s002680010174. (Pubitemid 30461212)
34. Castro P, Eknaes M, Teixeira MR, et al. Adenomas and follicular carcinomas of the thyroid display two major patterns of chromosomal changes. J Pathol 206(3):305-311, 2005. doi:10.1002/path.1772. (Pubitemid 40903194)
35. Castro P, Rebocho AP, Soares RJ, et al. PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab 91(1):213-220, 2006. doi:10.1210/jc.2005-1336. (Pubitemid 43069140)
36. Castro P, Roque L, Magalhaes J, Sobrinho-Simoes M. A subset of the follicular variant of papillary thyroid carcinoma harbors the PAX8-PPARgamma translocation. Int J Surg Pathol 13(3):235-238, 2005. doi:10.1177/ 106689690501300301. (Pubitemid 41117496)
37. Zhu Z, Gandhi M, Nikiforova MN, Fischer AH, Nikiforov YE. Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma An unusually high prevalence of ras mutations. Am J Clin Pathol 120(1):71-77, 2003. doi:10.1309/ND8D9LAJTRCTG6QD. (Pubitemid 37046372)
38. Yantiss RK, Cosar E, Fischer AH. Use of IMP3 in identification of carcinoma in fine needle aspiration biopsies of pancreas. Acta cytologica 52(2):133-138, 2008. (Pubitemid 351441122)